Login to Your Account



Da Volterra to smite the might of C. diff. with antibiotic adsorption technology

By Cormac Sheridan
Staff Writer

Monday, September 25, 2017

DUBLIN – Paris-based anti-infectives developer Da Volterra SA is planning a phase II trial of its lead product, DAV-132, in Europe in the coming months and is also looking to open an IND in the U.S. shortly.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription